New treatment for C. difficile

A new, but costly, class of antibiotic has been approved for treating Clostridium difficile in Australia.

Fidaxomicin (Dificid), the first of a new class of macrocyclic antibiotics, will be available from 14 May after receiving approval from the Therapeutic Goods Administration last month.

The new oral antibiotic has a narrow spectrum of activity against gram positive anaerobes and is batericidal against C. difficile.

It has no action against gram negative bacteria and has minimal systemic absorption.

Recent studies published in the